Portfolio company Therini Bio achieves major milestone with first patient dosed in Alzheimer's Phase 1b trial 7/29/2025 Category: PORTFOLIO NEWS
NUCLIDIUM raises €84 Million Series B to advance copper-based radiopharmaceutical platform for precision oncology 7/10/2025 Category: INVESTMENTS
Angelini Ventures invests in Elkedonia's breakthrough depression treatment 6/11/2025 Category: INVESTMENTS
Angelini Ventures backs Therini Bio's innovative approach to Alzheimer's and Retinal Diseases 5/14/2025 Category:
Angelini Ventures co-leads $45M Series B in Singapore-based Nuevocor, expanding into cardiovascular therapeutics 5/6/2025 Category: INVESTMENTS
Join our growing Team: Angelini Ventures seeks Biotech Investment Professional 4/22/2025 Category: TALENT
Angelini Ventures